Alphyn Biologics and AB-101

Alphyn Biologics is improving therapy for diseases with its platform AB-101 patent-pending biomaterial that has over 40 bio-active compounds.  AB-101’s over 40 bioactive allow it to both treat and cure many different diseases, and, provide multiple ways to attack each disease, leading the way in a new class of drugs called Multi-target Therapeutics.

Alphyn’s first product targets Methicillin-resistant Staphylococcus aureus (MRSA) skin infections.  MRSA is difficult to treat because it is resistant to the commonly used antibiotics.  The CDC considers MRSA, sometimes called a “superbug”, one of the biggest threats to human health.1  The current topical drugs of choice for treating MRSA are reported ineffective 30 – 80% of the time and are declining in efficacy as MRSA resistance grows.2, 3  Alphyn’s Multi-target Therapeutic for MRSA drug resistant infections is expected to be highly efficacious and fight development of resistance.

1 Need citation from SK
2  High Prevalence of Mupirocin Resistance in Staphylococcus aureus Isolates from a Pediatric Population. Antonov et al. American Society for Microbiology.  2015.
3  Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. Poovelikunnel et al. Journal of Antimicrobial Chemotherapy.  2015.

Alphyn is currently projecting its second pipeline product to be a topical prescription product to treat Basal Cell Carcinoma (BCC), a type of skin cancer accounting for approximately 80% of all skin cancers.1  BCC treatment can be complex, lengthy, painful, and may result in ugly scars.2  Alphyn’s Multi-target Therapeutics for BCC treatment is expected to be highly efficacious and not have the problems or side effects of current therapies.

Alphyn’s initial products, which utilize AB-101, solve two of the largest medical challenges to humankind – infectious skin diseases, including drug-resistant infections and skin cancer.